Liu, Si-Yang Maggie
Tu, Hai-Yan
Wei, Xue-Wu http://orcid.org/0000-0001-6865-8923
Yan, Hong-Hong
Dong, Xiao-Rong
Cui, Jiu-Wei
Zhou, Zhen
Xu, Chong-Rui http://orcid.org/0000-0002-3474-2809
Zheng, Ming-Ying
Li, Yang-Si
Wang, Zhen
Bai, Xiao-Yan
Li, An-Na
Sun, Yue-Li
Huang, Jie
Lin, Jia-Xin
Ke, E. E.
Xu, Bing-Fei
Lu, Chang http://orcid.org/0000-0001-6504-6083
Du, Yingying
Chen, Yuan
Ma, Rui
Wang, Bu-Hai
Cang, Shun-Dong
Wang, Bin-Chao
Chen, Hua-Jun
Yang, Jin-Ji
Li, Yangqiu http://orcid.org/0000-0002-0974-4036
Zhou, Qing http://orcid.org/0000-0002-0478-176X
Wu, Yi-Long http://orcid.org/0000-0002-3611-0258
Funding for this research was provided by:
National Natural Science Foundation of China (82202997, 82072562)
Article History
Received: 11 December 2022
Accepted: 14 June 2023
First Online: 24 July 2023
Change Date: 27 July 2023
Change Type: Update
Change Details: In the version of this article initially published, the Abstract did not list the ClinicalTrials.gov identifiers NCT03574402 and NCT03605602, which are now amended in the HTML and PDF versions of the article.
Competing interests
: Y.-L.W. reports getting honoraria from AstraZeneca, Lily, Roche, Pfizer, Boehringer Ingelheim, MSD Oncology, Bristol-Myers Squibb/China, Hengrui Pharmaceutical and BeiGene Beijing; consulting and advisory services for AstraZeneca, Roche and Takeda; and getting research funding from Roche, Boehringer Ingelheim, Pfizer and BMS. Q.Z. reports honoraria from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, MSD, Pfizer, Roche and Sanofi outside the submitted work. The remaining authors declare no competing interests.